MUMBAI, April 21, 2026: Hair loss affects a large proportion of the population, with up to 50% of men experiencing visible thinning by the age of 50 and a significant number of women affected by midlife. While autologous hair restoration treatments such as Platelet-Rich Plasma (PRP) and Growth Factor Concentrate (GFC) have become a staple in hair restoration clinics, a new scientific commentary is calling for an evolution in how we approach regenerative hair therapy. In response, experts are now pointing to Precision Re-engineered Efficacy Optimisation as a new conceptual framework designed to address this variability by enabling more defined and reproducible biological signalling in regenerative hair therapy.
“Autologous therapies are ‘noisy’ biological mixture. The ‘natural’ element of autologous hair regeneration protocols (PRP/GFC) is also its greatest weakness. Platelet yield, leukocyte content, activation method, centrifugation protocol, and device design can all meaningfully affect the results”, explained Dr Debraj Shome, Clinical Scientists and Research Mentor, QR678®. “In addition, patient-to-patient differences in baseline platelet counts and physiology further contribute to variability. Real-world performance of autologous therapies (PRP, GFC) can vary from patient to patient, and even across treatment sessions in the same individual”, Dr Shome added.
At a biological level, hair follicle behaviour is regulated by a complex interplay of signalling pathways that determine whether a follicle remains in the growth (anagen) phase or transitions into regression (catagen). Autologous preparations, by their nature, deliver a heterogeneous mix of growth factors, including both stimulatory and inhibitory signals. This can result in a diluted or conflicting biological message at the follicular level, where regenerative signals may be counterbalanced by factors associated with regression or inflammation.
“While PRP contains growth boosters like PDGF and VEGF, it also carries ‘brake’ signals or inhibitory factors like TGF-β and FGF5, which can inadvertently tell the hair to stop growing. This internal tug-of-war is likely why some patients see a thick mane while others see no change at all. If we look at the evolution of regenerative therapies more broadly, there is a clear shift toward reducing variability at its source. In the context of hair restoration, this means moving away from relying entirely on patient-derived biology and toward approaches where the composition, concentration, and signalling profile are more clearly defined”, commented Dr Raji Patil, Head of Medical Affairs, QR678®.
Due to the high variability of analogous PRP, experts feel a rational future direction is the translation of PRP biology into a compositionally defined, standardised formulation: a PRP-inspired, precision bio-engineered efficacy optimisation-oriented growth factor concentrate. Unlike traditional PRP, the bio-engineered, biomimetic Analog would be:
- Weighted toward Growth: Intentionally enriched with high, reproducible doses of PDGF.
- Filtered for Success: Designed to exclude or minimise inhibitory factors like TGF-β that trigger hair shedding
- Clinically Predictable: Not dependent on the patient’s baseline platelet count, making it a viable option for those with low platelet reserves or those who are poor candidates for frequent blood draws.
Dr Rinky Kapoor, Clinical Scientists and Research Mentor, QR678® opined, “For the Indian market, where the demand for hair restoration is growing at a CAGR of over 5%, this shift represents a move towards ‘Precision Trichology’. While bioengineered mimetics offer a robust mechanistic rationale, the next step for the industry is rigorous, transparent comparative trials to validate that these standardised constructs can outperform the traditional ‘in-office’ centrifuge. This does not replace existing treatments, but it does provide a framework for improving consistency and reproducibility. Over time, this kind of approach can help clinicians build more structured protocols and generate data that is easier to interpret and apply in practice.”
Emerging clinical evidence highlights the potential of a defined, growth factor–inspired approach in managing non-scarring hair loss. In a pilot randomised comparative study, this framework demonstrated a reduction in hair fall of over 65% after five sessions, with improvements better maintained at 12 months compared to conventional PRP. Patients also showed gains in global photographic assessment scores, along with increases in hair thickness and terminal hair counts, and a reduction in finer hairs. Supporting laboratory findings indicated reduced oxidative stress, improved cellular responses, and enhanced repair activity in key hair follicle cells, providing biological plausibility for the clinical outcomes. Together, these findings point toward a more standardised and potentially more durable approach in hair loss management.
As the field moves toward 2027, the focus is shifting from simply “injecting platelets” to “delivering the right biological message” to the hair follicle.
About QR678®
Founded in 2009 by cosmetic surgeon Dr Debraj Shome and dermatologist Dr Rinky Kapoor, QR678® is a clinically developed, non-surgical hair regeneration therapy platform based on growth factor science and regenerative dermatology. Developed to address common forms of hair loss, such as androgenetic alopecia and telogen effluvium, the platform delivers products with a targeted combination of biomimetic peptides and growth factors into the scalp to support follicular function, improve hair density, and enhance hair thickness.
Over the years, the QR678® platform has released multiple products globally which offer standardised treatments for hair loss, reducing the variability associated with patient-derived treatments. Administered by trained medical professionals, QR678® platform derived therapies are minimally invasive and positioned within a broader shift toward precision-driven, reproducible approaches in hair restoration.
